Phase II Study of FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 20 Jun 2019 Status changed from active, no longer recruiting to completed.
- 23 Apr 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 23 Apr 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.